These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35793677)

  • 1. Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection.
    Boucau J; Chew KW; Choudhary MC; Deo R; Regan J; Flynn JP; Crain CR; Hughes MD; Ritz J; Moser C; Dragavon JA; Javan AC; Nirula A; Klekotka P; Greninger AL; Coombs RW; Fischer WA; Daar ES; Wohl DA; Eron JJ; Currier JS; Smith DM; ; Li JZ; Barczak AK;
    Cell Rep Med; 2022 Jul; 3(7):100678. PubMed ID: 35793677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection.
    Boucau J; Chew KW; Choudhary M; Deo R; Regan J; Flynn JP; Crain CR; Hughes MD; Ritz J; Moser C; Dragavon JA; Javan AC; Nirula A; Klekotka P; Greninger AL; Coombs RW; Fischer WA; Daar ES; Wohl DA; Eron JJ; Currier JS; Smith DM; Li JZ; Barczak AK;
    medRxiv; 2021 Dec; ():. PubMed ID: 35018382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2.
    Choudhary MC; Deo R; Evering TH; Chew KW; Giganti MJ; Moser C; Ritz J; Regan J; Flynn JP; Crain CR; Wohl DA; Currier JS; Eron JJ; Margolis D; Zhu Q; Zhon L; Ya L; Greninger AL; Hughes MD; Smith D; Daar ES; Li JZ
    J Infect Dis; 2024 Aug; 230(2):394-402. PubMed ID: 38716969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
    Zhang L; Poorbaugh J; Dougan M; Chen P; Gottlieb RL; Huhn G; Beasley S; Daniels M; Ngoc Vy Trinh T; Crisp M; Freitas JJ; Vaillancourt P; Patel DR; Nirula A; Kallewaard NL; Higgs RE; Benschop RJ
    Front Immunol; 2021; 12():790469. PubMed ID: 34956222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies.
    Vellas C; Del Bello A; Debard A; Steinmeyer Z; Tribaudeau L; Ranger N; Jeanne N; Martin-Blondel G; Delobel P; Kamar N; Izopet J
    Clin Microbiol Infect; 2022 Jan; 28(1):139.e5-139.e8. PubMed ID: 34537363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial.
    Choudhary MC; Chew KW; Deo R; Flynn JP; Regan J; Crain CR; Moser C; Hughes MD; Ritz J; Ribeiro RM; Ke R; Dragavon JA; Javan AC; Nirula A; Klekotka P; Greninger AL; Fletcher CV; Daar ES; Wohl DA; Eron JJ; Currier JS; Parikh UM; Sieg SF; Perelson AS; Coombs RW; Smith DM; Li JZ;
    Nat Microbiol; 2022 Nov; 7(11):1906-1917. PubMed ID: 36289399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
    JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
    Hirsch C; Park YS; Piechotta V; Chai KL; Estcourt LJ; Monsef I; Salomon S; Wood EM; So-Osman C; McQuilten Z; Spinner CD; Malin JJ; Stegemann M; Skoetz N; Kreuzberger N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD014945. PubMed ID: 35713300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.
    Brehm TT; Pfefferle S; von Possel R; Karolyi M; Zoufaly A; Wichmann D; Kobbe R; Emmerich P; Nörz D; Aepfelbacher M; Schulze Zur Wiesch J; Addo MM; Schmiedel S; Lütgehetmann M
    J Med Virol; 2022 Oct; 94(10):5038-5043. PubMed ID: 35662058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PK/PD modeling links accelerated resolution of COVID-19-related clinical symptoms to SARS-CoV-2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together.
    Ernest CS; Chien JY; Patel DR; Chigutsa E
    CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):721-730. PubMed ID: 35289125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab.
    Sims JT; Poorbaugh J; Chang CY; Holzer TR; Zhang L; Engle SM; Beasley S; Doman TN; Naughton L; Higgs RE; Kallewaard N; Benschop RJ
    J Transl Med; 2022 Mar; 20(1):134. PubMed ID: 35303909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
    Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual Monoclonal Antibodies on Sars-Cov-2 Alpha and Delta Variants: Clinical and Virological Efficacy.
    Ferré VM; Peiffer-Smadja N; Kramer L; Coppée R; Kante A; Debarge M; Choquet C; Saint Joannis T; Bouzid D; Messika J; Le Grand J; Thy M; Kernéis S; Descamps D; Visseaux B; Ghosn J
    Microbiol Spectr; 2022 Oct; 10(5):e0215222. PubMed ID: 36125289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series.
    Boeckel GR; Hölscher SD; Bürger C; Jacob T; Krekeler C; Shumilov E; Reicherts C; Bleckmann A; Lenz G; Vollenberg R; Tepasse PR
    Curr Oncol; 2022 Mar; 29(4):2312-2325. PubMed ID: 35448162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical Trial.
    Chew KW; Moser C; Daar ES; Wohl DA; Li JZ; Coombs R; Ritz J; Giganti M; Javan AC; Li Y; Malvestutto C; Klekotka P; Price K; Nirula A; Fischer W; Bala V; Ribeiro RM; Perelson AS; Fletcher CV; Eron JJ; Currier JS; Hughes MD; Smith DM;
    medRxiv; 2021 Dec; ():. PubMed ID: 34981077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study.
    Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E;
    Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrial fibrillation with aberrant ventricular conduction after receiving Bamlanivimab/Etesevimab: a case report.
    Palazzo AG; Zizza A; Nuzzo M; Urciuoli C; Scardia S; Romano A; Guido M; Grima P
    Curr Med Res Opin; 2022 Jul; 38(7):1055-1057. PubMed ID: 35608093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection.
    Hwang YC; Lu RM; Su SC; Chiang PY; Ko SH; Ke FY; Liang KH; Hsieh TY; Wu HC
    J Biomed Sci; 2022 Jan; 29(1):1. PubMed ID: 34983527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load.
    Dougan M; Azizad M; Mocherla B; Gottlieb RL; Chen P; Hebert C; Perry R; Boscia J; Heller B; Morris J; Crystal C; Igbinadolor A; Huhn G; Cardona J; Shawa I; Kumar P; Blomkalns A; Adams AC; Van Naarden J; Custer KL; Knorr J; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Sabo J; Patel DR; Dabora MC; Williams M; Klekotka P; Shen L; Skovronsky DM; Nirula A
    Clin Infect Dis; 2022 Aug; 75(1):e440-e449. PubMed ID: 34718468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic monoclonal antibodies for COVID-19 management: an update.
    Chavda VP; Prajapati R; Lathigara D; Nagar B; Kukadiya J; Redwan EM; Uversky VN; Kher MN; Patel R
    Expert Opin Biol Ther; 2022 Jun; 22(6):763-780. PubMed ID: 35604379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.